FDA Approves First Myostatin Inhibitor: What Isembyld Means for the Future of Muscle Growth
For decades, the bodybuilding world has treated myostatin like the Loch Ness Monster with a lab coat. Everybody has heard of it. Everybody knows somebody who supposedly knows somebody who inhibited it. And every few years another vial appears on the Internet promising that you’ll wake up looking like a Belgian Blue bull provided you’re willing to inject something manufactured behind a back-alley noodle shop. Well, something rather important just happened. On Sept. 11, the FDA approved Scholar Rock’s Isembyld—apitegromab-mstn—for adults and children age 2 and older with spinal muscular atrophy (SMA) who are already receiving an SMN2-targeted therapy. More importantly for our little corner of the universe, it’s the first approved SMA treatment designed specifically to target the muscle itself. And the target is myostatin. News The Future of Steroids and PEDs Explore the advancements being made to PEDs, emerging drugs, an...